Zika Virus Purified Inactivated Vaccine (ZPIV) Accelerated Vaccination Schedule Study (Z001)

• ClinicalTrials.gov Identifier: NCT02937233
• Recruitment Status: Completed
• First Posted: October 18, 2016
• Last Update Posted: August 23, 2018
• Sponsor: Kathryn Stephenson
• Collaborators: Walter Reed Army Institute of Research (WRAIR); National Institute of Allergy and Infectious Diseases (NIAID)
• Information provided by (Responsible Party): Kathryn Stephenson, Beth Israel Deaconess Medical Center

Study Description

Brief Summary:

This is a phase 1 trial of one or more administrations of Zika Virus Purified Inactivated Vaccine (ZPIV). The trial will be conducted under a placebo controlled, double-blind, randomized allocation of study product. There are four groups in the study. Each group is testing a different vaccine schedule.

Condition or disease	Intervention/treatment	Phase
Zika	Biological: Zika Virus Purified Inactivated Vaccine; Other: Placebo	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 36 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Prevention
• Official Title: A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an Accelerated Vaccination Schedule With a Zika Virus Purified Inactivated Vaccine Plus Alum Adjuvant in Healthy Adults
• Actual Study Start Date: December 8, 2016
• Actual Primary Completion Date: June 4, 2018
• Actual Study Completion Date: June 4, 2018

Arms and Interventions

Arm	Intervention/treatment
Experimental: 4 Week Schedule; Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 4	Biological: Zika Virus Purified Inactivated Vaccine; Other: Placebo
Experimental: 2 Week Schedule; Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 2	Biological: Zika Virus Purified Inactivated Vaccine; Other: Placebo
Experimental: Single Vaccination Schedule; Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 only	Biological: Zika Virus Purified Inactivated Vaccine; Other: Placebo

Outcome Measures

Primary Outcome Measures :

1. Incidence, intensity, and relationship to vaccination of solicited local and systemic adverse events [ Time Frame: 7 days following each vaccination ]
2. Incidence, intensity, and relationship to vaccination of unsolicited local and systemic adverse events [ Time Frame: 28 days following each vaccination ]
3. Incidence, intensity, and relationship to vaccination of serious local and systemic adverse events [ Time Frame: 365 days following each vaccination ]

Secondary Outcome Measures :

1. ZIKV microneutralization Log10 MN50 titers [ Time Frame: 28 days following last vaccination, and at 6 months ]
2. Zika Env-specific Log10 endpoint ELISA titers [ Time Frame: 28 days following last vaccination, and at 6 months ]
3. Zika Plaque reduction neutralization test titer [ Time Frame: 28 days following last vaccination, and at 6 months ]
4. IFN-γ ELISPOT responses to prM, Env, Cap, and NS1 peptides [ Time Frame: 28 days following last vaccination, and at 6 months ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 50 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Age 18-50 years old.
2. Ability and willingness to provide informed consent.
3. Assessment of understanding: completion of a questionnaire prior to first screening procedure; verbally demonstrate understanding of all questionnaire items answered incorrectly.
4. Available for the duration of the trial.
5. Good general health as shown by medical history, physical exam, and screening laboratory tests.

6. The following laboratory parameters:

   • Hematology

     • Hemoglobin ≥10.5 g/dL for women; ≥11 g/dL for men
     • Absolute Neutrophil Count (ANC): ≥1000/mm3
     • Platelets: 125,000 to 550,000/mm3

   • Chemistry

     • Creatinine: <1.1 x upper limit of normal (ULN)
     • AST: <1.25 x ULN
     • ALT: <1.25 x ULN

   • Normal urinalysis

     • Negative urine glucose.
     • Negative or trace urine protein.
     • Negative or trace urine hemoglobin (if trace hemoglobin is present on dipstick, a microscopic urinalysis within institutional range).
7. All female participants must be willing to undergo serum or urine beta human chorionic gonadotropin pregnancy tests at time points indicated in the Schedule of Procedures and must test negative prior to vaccination.
8. All sexually active males (unless anatomically sterile) must be willing to use an effective method of contraception (such as consistent condom use) from the day of first vaccination until Week 12.

9. If a woman of child-bearing potential, committed to use an effective method of contraception when sexually active with men until Week 12, including:

   • Condoms (male or female) with or without spermicide.
   • Diaphragm or cervical cap with spermicide.
   • Intrauterine device.
   • Hormonal contraception.
   • Successful vasectomy in the male partner (considered successful if a woman reports that a male partner has [1] documentation of azoospermia by microscopy, or [2] a vasectomy more than 2 years ago with no resultant pregnancy despite sexual activity post-vasectomy).
   • Not be of reproductive potential, such as having undergone hysterectomy, bilateral oophorectomy, or tubal ligation.

Exclusion Criteria:

1. History of known flavivirus infection or previous receipt of flavivirus vaccine.
2. Positive serology for HIV-1, Hepatitis B surface antigen, or anti-hepatitis C virus antibodies prior to enrollment.
3. Planned travel to areas with active Zika virus transmission during the study period.
4. Recent (within 3 weeks) travel to an area with active Zika virus transmission.
5. Current or planned participation in another clinical trial of an experimental agent during the study period.
6. Pregnant or lactating.
7. Any condition, including any clinically significant acute or chronic medical condition, for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
8. Use of anticancer, antituberculosis or other medications considered significant by the investigator within the previous 6 months.
9. Receipt of live-attenuated vaccine within the previous 60 days or planned receipt within 60 days after vaccination with Investigational Product (within 14 days for live attenuated influenza vaccine [LAIV]); or receipt of other vaccine (e.g., influenza, pneumococcal), allergy treatment with antigen injections or tuberculin skin test within the previous 14 days or planned receipt within 14 days after vaccination with Investigational Product
10. Receipt of blood transfusion or blood-derived products within the previous 3 months.
11. Previous severe local or systemic reactions to vaccination.
12. History of splenectomy
13. History of seizure in the last 3 years (participants with a history of seizures who have neither required medications nor had a seizure for 3 years are not excluded)
14. Known autoimmune disease

15. Asthma other than mild, well-controlled asthma. Exclude participants who:

    1. Use a bronchodilator (beta 2 agonist) daily, or
    2. In the past year have (any of the following):

    i. Had > 1 exacerbation of symptoms treated with oral steroids ii. Routinely used moderate to high dose inhaled corticosteroids (e.g., more than the equivalent of 250 mcg fluticasone; 400 mcg budesonide; 500 mcg beclomethasone; or 1000 mcg triamcinolone/flunisolide, as a daily dose) or theophylline iii. Needed emergency care, urgent care, hospitalization, or intubation for asthma c. Prophylactic bronchodilator use prior to exercise is not exclusionary

16. Diabetes mellitus type 1 or type 2, including cases controlled with diet alone. (Not excluded: history of isolated gestational diabetes.)
17. Thyroidectomy, or thyroid disease requiring medication during the last 12 months
18. Angioedema within the last 3 years if episodes are considered serious or have required medication within the last 2 years

19. Uncontrolled Hypertension:

    1. If a person has been diagnosed with hypertension during screening or previously, exclude for hypertension that is not well controlled. Well- controlled hypertension is defined as blood pressure consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic, with or without medication, with only isolated, brief instances of higher readings, which must be ≤ 150 mm
    2. If a person has NOT been diagnosed with hypertension during screening or previously, exclude for systolic blood pressure ≥ 150 mm Hg at enrollment or diastolic blood pressure ≥ 90 mm Hg at enrolment
20. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions)
21. Malignancy (Not excluded: a participant with a surgical excision and subsequent observation period that in the investigator's estimation has a reasonable assurance of sustained cure or is unlikely to recur during the study period)
22. Psychiatric condition that compromises safety of the participant or precludes compliance with the protocol, specifically excluding persons with psychoses within the past 3 years, ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years

Contacts and Locations

Locations

United States, Massachusetts

Center for Virology and Vaccine Research Clinical Trials Unit, Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215

Sponsors and Collaborators

Kathryn Stephenson

Walter Reed Army Institute of Research (WRAIR)

National Institute of Allergy and Infectious Diseases (NIAID)

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Stephenson KE, Tan CS, Walsh SR, Hale A, Ansel JL, Kanjilal DG, Jaegle K, Peter L, Borducchi EN, Nkolola JP, Makoni T, Fogel R, Bradshaw C, Tyler A, Moseley E, Chandrashekar A, Yanosick KE, Seaman MS, Eckels KH, De La Barrera RA, Thompson J, Dawson P, Thomas SJ, Michael NL, Modjarrad K, Barouch DH. Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2020 Sep;20(9):1061-1070. doi: 10.1016/S1473-3099(20)30085-2. Epub 2020 May 6.

Modjarrad K, Lin L, George SL, Stephenson KE, Eckels KH, De La Barrera RA, Jarman RG, Sondergaard E, Tennant J, Ansel JL, Mills K, Koren M, Robb ML, Barrett J, Thompson J, Kosel AE, Dawson P, Hale A, Tan CS, Walsh SR, Meyer KE, Brien J, Crowell TA, Blazevic A, Mosby K, Larocca RA, Abbink P, Boyd M, Bricault CA, Seaman MS, Basil A, Walsh M, Tonwe V, Hoft DF, Thomas SJ, Barouch DH, Michael NL. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet. 2018 Feb 10;391(10120):563-571. doi: 10.1016/S0140-6736(17)33106-9. Epub 2017 Dec 5. Erratum in: Lancet. 2020 Jun 20;395(10241):1906.

• Responsible Party: Kathryn Stephenson, Assistant Professor of Medicine, Beth Israel Deaconess Medical Center
• ClinicalTrials.gov Identifier: NCT02937233
• Other Study ID Numbers: 2016P000268
• First Posted: October 18, 2016
• Last Update Posted: August 23, 2018
• Last Verified: August 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

Keywords provided by Kathryn Stephenson, Beth Israel Deaconess Medical Center:

Zika; Vaccine; ZPIV

Additional relevant MeSH terms:

Zika Virus Infection; Arbovirus Infections; Vector Borne Diseases; Infections; Virus Diseases; Flavivirus Infections; Flaviviridae Infections; RNA Virus Infections